López-Farré A, Farré J, Sánchez de Miguel L, Romero J, Gómez J, Rico L, Casado S
Laboratorio de Nefrología, Hipertensión e Investigación Cardiovascular, Fundación Jiménez Díaz, Madrid.
Rev Esp Cardiol. 1998 Mar;51(3):171-7. doi: 10.1016/s0300-8932(98)74730-x.
In recent years, relevant changes have occurred in the knowledge of the cellular mechanisms regulating platelet aggregation and adhesion to the endothelial surface. In particular, major aspects of the interactions between platelets and endothelial cells and neutrophils have been clarified. These interactions involve not only thrombosis-promoting or thrombosis-inhibiting properties but also several aspects of the regulation of vascular function. A new concept has progressively emerged showing thrombosis as a multicellular event in which cell-to cell interactions between platelets, neutrophils, and endothelium regulate the size of a growing thrombus. In brief, there is consistent evidence showing that two vasodilating mediators produced by endothelial cells and neutrophils (nitric oxide and prostacyclin) have antiaggregating platelet effects. Platelet activation is particularly relevant in myocardial ischemia, and several pharmacological strategies have been devised to prevent intravascular platelet activation. Aspirin remains a keystone of these preventive and damage-limiting strategies. Current knowledge maintains that low doses of aspirin decrease in vivo platelet aggregation by a selective inhibitory effect on thromboxane A2 production by platelets with maintenance of prostacyclin production by the endothelium. We have recently focussed our research on the basis that the antiaggregating effect of aspirin could be explained not only by the above-mentioned effects on thromboxane A2 synthesis, but also through its action on neutrophils. Our in vitro and ex vivo studies have demonstrated that neutrophils enhance the antiaggregating effects of acetylsalicilic acid on platelets. We have shown that acetylsalicilic acid stimulates nitric oxide production on neutrophils inhibiting the aggregating effects of thrombin, ADP or epinephrine on platelets. the role of the neutrophils in ischemic events enhancing the tissue damage through the release of several proteases, reactive oxygen species and tumor necrosis factor-alpha has been extensively demonstrated. In an experimental model of acute ischemia/reperfusion in rabbits, we have shown that acetylsalicilic acid is able to enhance the nitric oxide production by neutrophils providing a potential mechanism for the beneficial action of aspirin in the myocardial infarction. Further research is needed to assess the mechanisms of the action of aspirin during the thrombotic phenomena and its effects on the different types of cells that compound the microvascular environment.
近年来,在调节血小板聚集及与内皮表面黏附的细胞机制方面出现了相关变化。特别是,血小板与内皮细胞及中性粒细胞之间相互作用的主要方面已得到阐明。这些相互作用不仅涉及促血栓形成或抗血栓形成特性,还涉及血管功能调节的多个方面。一个新的概念逐渐形成,将血栓形成视为一个多细胞事件,其中血小板、中性粒细胞和内皮细胞之间的细胞间相互作用调节着不断增长的血栓大小。简而言之,有确凿证据表明内皮细胞和中性粒细胞产生的两种血管舒张介质(一氧化氮和前列环素)具有抗血小板聚集作用。血小板活化在心肌缺血中尤为重要,并且已经设计了多种药理学策略来预防血管内血小板活化。阿司匹林仍然是这些预防和损伤限制策略的关键。目前的知识认为,低剂量阿司匹林通过对血小板血栓素A2生成的选择性抑制作用降低体内血小板聚集,同时维持内皮细胞前列环素的生成。我们最近将研究重点放在阿司匹林的抗聚集作用不仅可以通过上述对血栓素A2合成的作用来解释,还可以通过其对中性粒细胞的作用来解释这一基础上。我们的体外和离体研究表明,中性粒细胞增强了乙酰水杨酸对血小板的抗聚集作用。我们已经表明,乙酰水杨酸刺激中性粒细胞产生一氧化氮,抑制凝血酶、二磷酸腺苷或肾上腺素对血小板的聚集作用。中性粒细胞通过释放多种蛋白酶、活性氧和肿瘤坏死因子-α在缺血事件中增强组织损伤的作用已得到广泛证实。在兔急性缺血/再灌注的实验模型中,我们已经表明乙酰水杨酸能够增强中性粒细胞产生一氧化氮,这为阿司匹林在心肌梗死中的有益作用提供了一种潜在机制。需要进一步研究来评估阿司匹林在血栓形成现象中的作用机制及其对构成微血管环境的不同类型细胞的影响。